Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2024 08:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024

Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
December 14, 2023 08:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences Announces CEO Catherine Sabatos-Peyton to Participate in Upcoming Biotech Events

WATERTOWN, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that stops immune evasion from where it starts in the tumor, announced...
October 25, 2023 08:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences to Present New Mechanistic Data on the Role of Pin1 in Modulating the Fibroblast – Cancer Axis at SITC 2023

WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building precision therapies to outsmart cancer, announced that data supporting development of a...
June 26, 2023 07:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint

Research foundational to Larkspur’s newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature WATERTOWN, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences revealed...
May 30, 2023 08:00 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences to Participate in the 2023 BIO International Convention

WATERTOWN, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, announced that they will be...
May 23, 2023 05:30 ET | Source: Larkspur Biosciences, Inc.

Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer

Addressing the Key Bottlenecks in the Tumor Microenvironment That Allow a Tumor to Subvert the Immune System Financing Co-led by Polaris Innovation Fund, 3E Bioventures Capital, and Takeda...